Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

November 12, 2026

Consolidated Financial Results for the Six Months Ended September 30, 2026 (Under Japanese GAAP)

Company name: SUZUKEN CO., LTD.
Listing: Tokyo Stock Exchange, Nagoya Stock Exchange, Sapporo Securities Exchange
Securities code: 9987
URL: https://www.suzuken.co.jp
Representative: Shigeru Asano President and CEO
Inquiries: Satoshi Hashimoto Executive Officer and General Manager of Business Administration Department
Telephone: +81-52-961-2331
Scheduled date to file semi-annual securities report: November 13, 2026
Scheduled date to commence dividend payments: December 10, 2026
Preparation of supplementary material on financial results: Yes
Holding of financial results briefing: Yes

(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated financial results for the six months ended September 30, 2026 (from April 1, 2026 to September 30, 2026)

(1) Consolidated operating results (cumulative) (Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
Six months ended	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
September 30, 2026	1,281,025	5.1	13,561	(20.0)	15,343	(14.9)	12,974	(20.1)
September 30, 2025	1,219,440	1.8	16,958	(0.8)	18,032	6.0	16,241	(19.9)

Note: Comprehensive income For the six months ended September 30, 2026: ¥ 11,285 million [(18.5) %]
For the six months ended September 30, 2025: ¥ 13,846 million [(17.0) %]

	Basic earnings per share	Diluted earnings per share
Six months ended	Yen	Yen
September 30, 2026	96.07	-
September 30, 2025	114.05	-

Note: The Company conducted a stock split of its common stock, with each share split into two (2) shares, effective October 1, 2026. Basic earnings per share has been calculated as if the stock split had taken place at the beginning of the previous fiscal year.

(2) Consolidated financial position

	Total assets	Net assets	Equity-to-asset ratio
As of	Millions of yen	Millions of yen	%
September 30, 2026	1,217,937	419,005	34.4
March 31, 2026	1,155,766	416,012	36.0

Reference: Equity
As of September 30, 2026: ¥ 418,809 million
As of March 31, 2026: ¥ 415,876 million

2. Cash dividends

	Annual dividends per share				
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended March 31, 2026	-	50.00	-	50.00	100.00
Fiscal year ending March 31, 2027	-	60.00			
Fiscal year ending March 31, 2027 (Forecast)			-	30.00	-

Notes: 1. Revisions to the forecast of cash dividends most recently announced: None

2. The Company conducted a stock split of its common stock, with each share split into two (2) shares, effective October 1, 2026. The forecast year-end dividend per share for the fiscal year ending March 31, 2027 reflects the impact of this stock split, and therefore the total annual dividend per share is listed as "-." If the stock split is not taken into account, the forecast year-end dividend per share for the fiscal year ending March 31, 2027 would be ¥60, and the total annual dividend per share would be ¥120.

3. Consolidated financial results forecast for the fiscal year ending March 31, 2027 (from April 1, 2026 to March 31, 2027)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Basic earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Full year	2,563,000	3.1	31,200	(14.2)	34,300	(13.7)	25,000	(34.4)	184.81

Notes: 1. Revisions to the financial results forecast most recently announced: None

2. The Company conducted a stock split of its common stock, with each share split into two (2) shares, effective October 1, 2026. Basic earnings per share in the full-year consolidated financial results forecast for the fiscal year ending March 31, 2027 reflects the impact of this stock split. If the stock split is not taken into account, basic earnings per share would be ¥369.62.

*** Notes**

(1) Significant changes in the scope of consolidation during the period: None

Newly included: - companies( )

Excluded: - companies( )

(2) Adoption of accounting treatment specific to the preparation of semi-annual consolidated financial statements: None

(3) Changes in accounting policies, changes in accounting estimates, and restatement

(i) Changes in accounting policies due to revisions to accounting standards and other regulations: None

(ii) Changes in accounting policies due to other reasons: None

(iii) Changes in accounting estimates: None

(iv) Restatement: None

(4) Number of issued shares (common shares)

(i) Total number of issued shares at the end of the period (including treasury shares)

As of September 30, 2026	144,334,408 shares
As of March 31, 2026	144,334,408 shares

(ii) Number of treasury shares at the end of the period

As of September 30, 2026	10,966,144 shares
As of March 31, 2026	9,058,718 shares

(iii) Average number of shares outstanding during the period (cumulative from the beginning of the fiscal year)

Six months ended September 30, 2026	135,043,419 shares
Six months ended September 30, 2025	142,409,358 shares

Note: The Company conducted a stock split of its common stock, with each share split into two (2) shares, effective October 1, 2026. The total number of issued shares at the end of the period (including treasury shares), the number of treasury shares at the end of the period, and the average number of shares outstanding during the period (cumulative from the beginning of the fiscal year) have been calculated as if the stock split had taken place at the beginning of the previous fiscal year.

* Semi-annual financial results reports are exempt from review conducted by certified public accountants or an audit firm.

* Proper use of earnings forecasts, and other special matters

Earnings forecasts and other statements about the future that are included in this material are based on information currently in the possession of the Company, and certain conditions judged reasonable by the Company. These statements do not guarantee that the Company will achieve its earnings forecasts. In addition, actual results, etc., may differ significantly due to various factors. For notes, etc., on the conditions for earnings forecasts and the use of earnings forecasts, please refer to “1. Overview of Operating Results (3) Explanation of Forecasts of Consolidated Financial Results and Other Forward-Looking Statements” on page 7 of the attached documentation.

○ Contents of Attached Documentation

1. Overview of Operating Results 2
(1) Overview of Operating Results for the Semi-Annual Period 2
(2) Overview of Financial Position for the Semi-Annual Period 7
(3) Explanation of Forecasts of Consolidated Financial Results and Other Forward-Looking Statements 7
2. Consolidated Semi-Annual Financial Statements and Key Notes 8
(1) Consolidated Semi-Annual Balance Sheets 8
(2) Consolidated Semi-Annual Statements of Income and Comprehensive Income 10
Consolidated Semi-Annual Statement of Income 10
Consolidated Semi-Annual Statement of Comprehensive Income 11
(3) Consolidated Semi-Annual Statement of Cash Flows 12
(4) Notes on Consolidated Semi-Annual Financial Statements 14
<Notes on the Assumption of the Company as a Going Concern> 14
<Notes on Significant Changes in the Amount of Shareholders' Equity> 14
<Notes on Segment Information etc.> 14
<Important Subsequent Events> 17

1. Overview of Operating Results

(1) Overview of Operating Results for the Semi-Annual Period

During the six months ended September 30, 2026, currency market fluctuations continued, while inflation persisted amid rising electricity, energy, and raw material prices due to various factors, including uncertainty surrounding the policy direction of the US administration. Furthermore, policy-driven wage hikes and growing labor shortages led to rising costs across various areas. Meanwhile, uncertainty remained over the ability to pass on these higher costs through price increases, as well as over the impact of heightened tensions in the Middle East, which emerged toward the end of the previous fiscal year, on crude oil prices and product procurement. Against this backdrop, the outlook for the domestic economy and corporate earnings remained uncertain.

In the healthcare sector, challenges related to the sustainability of the healthcare delivery system have become increasingly apparent, including increasing demand for medical care driven by the rapidly declining birthrate and aging population, shortages of medical and nursing care personnel, ensuring a stable supply of pharmaceuticals, appropriate inventory management of high-priced pharmaceuticals, and disaster response in local communities.

In addition, while the use of rapidly evolving and increasingly sophisticated generative AI and external cloud services is expanding across various settings, interest in the use of digital services is growing across society. At the same time, awareness of both the benefits and associated risks of such services is also increasing rapidly, particularly in light of recent incidents involving suspected AI-related data leaks and vulnerabilities in PHP[*1].

*1 PHP (PHP Hypertext Preprocessor)
: A programming language widely used in the development of websites and web applications.

Under these circumstances, the Suzuken Group has formulated a new Medium-Term Management Plan covering the period through the fiscal year ending March 31, 2029. This Plan represents a three-year period focused on translating the initiatives and investments the Group has pursued to date into tangible business results. Under the theme, “Our Third Beginning Toward Becoming a Health Creation Enterprise — Evolving into a next-generation wholesaler that goes beyond the conventional wholesale model —,” the Group is advancing three key initiatives: “Evolve into a next-generation wholesaler,” “Reconfigure the business portfolio,” and “Strengthen the management foundation.”

○ Theme
Our Third Beginning Toward Becoming a Health Creation Enterprise
— Evolving into a next-generation wholesaler that goes beyond the conventional wholesale model —

○ Slogan
Change Inspires Innovation
We view changes in the environment as an opportunity for growth and continually seek new ways to innovate.
Innovation Drives Change
That spirit of innovation will shape the future for the Suzuken Group.

○ Key Initiatives
（1） Evolve into a next-generation wholesaler
In our core pharmaceutical distribution business, we will take on the challenge of developing a fee-based business driven by our functions (i.e., monetizing our capabilities), in addition to the traditional margin-based business.
To evolve into a next-generation wholesaler, we will further enhance efficiency in the order-to-delivery process while ensuring a stable supply. At the same time, by earning fair compensation for services that address customers’ challenges, we will diversify our earnings structure and enhance value creation.
（2） Reconfigure the business portfolio
While maintaining the pharmaceutical distribution business as our core, we will work to evolve our business structure through the advancement of existing businesses and alliances with external partners. To adapt to changes in the environment without being constrained by traditional business frameworks, we will combine our functions and assets to transform toward higher value-added business models.
（3） Strengthen the management foundation
We recognize that developing human resources responsible for executing this Medium-Term Management Plan is essential to its successful implementation. Accordingly, we will strengthen the development and recruitment of personnel with expertise in digital transformation fields such as digital technologies and data analytics, in addition

to developing next-generation leaders in a planned manner.

We will also enhance Group-wide utilization of human resources and interdepartmental collaboration, while strengthening the management foundation that supports sustainable growth by fostering an environment in which diverse talent can fully demonstrate their capabilities.

During the six months ended September 30, 2026, the Group continued initiatives to create new value as part of its efforts to evolve into a next-generation wholesaler, a key pillar of the Medium-Term Management Plan, by combining the capabilities it has developed through its pharmaceutical distribution business with digital, logistics, and other capabilities. Specifically, the Group implemented various initiatives under the themes of “Responding to category shifts,” “Strengthening infrastructure,” and “Redesigning service offerings.”

Under “Responding to category shifts,” in response to the increasing prevalence of specialty and high-priced pharmaceuticals, the Group continued to promote the adoption of Cubixx, its traceability solution for specialty pharmaceuticals. As of the end of September, Cubixx had been deployed at 662 facilities, with 794 units installed nationwide, and contributed to reducing pharmaceutical disposal by approximately ¥7.0 billion in the fiscal year ended March 31, 2026. Going forward, the Group will further expand the adoption of Cubixx and enhance its integration with related services, while utilizing accumulated inventory and consumption data to optimize pharmaceutical distribution as a whole, including by improving the visibility of distribution inventories and enhancing demand forecasting.

Under “Strengthening infrastructure,” to maintain a stable supply of pharmaceuticals and other essential products even in the event of a disaster, the Group is developing business continuity functions using Medical Care Station (MCS)[*2], which supports multidisciplinary collaboration. These functions will enable the Group to confirm inventory levels and the safety of personnel at medical institutions, pharmacies, nursing care facilities, and other locations. This initiative has also been selected for a subsidy program of the Ministry of Health, Labour and Welfare. By combining the MCS network with the Group’s logistics capabilities, the Group is developing a framework to identify supplies needed during disasters and enable their rapid delivery.

Under “Redesigning service offerings,” the Group is working to expand customer touchpoints by combining in-person and digital channels. “medimo”[*3], a SaaS platform for medical documentation provided by medimo, Inc., which became a wholly owned subsidiary in February 2026, uses generative AI to automatically generate medical records and medication histories based on conversations during consultations, thereby reducing the workload of physicians and other healthcare professionals. During the six months ended September 30, 2026, medimo was introduced at more than 1,000 additional facilities, bringing the cumulative number of medical institutions using the service nationwide to more than 2,300 as of the end of September.

In addition to its in-person customer touchpoints with approximately 160,000 customers nationwide, the Group is rolling out digital services such as AI-MS[*4], which uses AI to provide information, with COLLABO Portal[*5], a platform for healthcare and nursing care professionals, serving as the foundation for these services. COLLABO ID, the common authentication platform that connects these services, had expanded to approximately 490,000 users as of the end of September, as the Group continues to explore new approaches to sales activities.

Going forward, the Group will continue to combine the capabilities it has developed, including logistics and customer touchpoints, with digital capabilities and the diverse capabilities of Group companies and partner companies. Through these efforts, the Group will contribute to the stable supply of pharmaceuticals, higher productivity in healthcare settings, and lower social costs, while advancing the commercialization of these capabilities and further evolving into a next-generation wholesaler.

As part of risk management efforts, the Group established the Information Security Practices Committee on April 1, 2025, as a practices committee under the Risk Management and Compliance Committee, which operates under the Board of Directors, to address increasingly sophisticated and serious information security risks, including the growing number of ransomware incidents. The Group is also responding to emerging risks, such as vulnerabilities in PHP, based on a Group-wide understanding of the situation.

In addition to preventing intrusions, the Group is strengthening its capabilities for early detection, containment, and

recovery to establish a framework that minimizes the impact of information security incidents on the stable supply of pharmaceuticals. Going forward, the Group will further promote the centralized monitoring and control of security levels across the Group, as well as their continuous enhancement and improvement.

Regarding shareholder returns, the Group announced a new shareholder return policy for the period of this Medium-Term Management Plan in May 2026. Under this policy, the Group promotes management with a strong focus on return on equity (ROE), and while preventing the excessive accumulation of net assets, it strives to enhance capital efficiency, and will pay dividends and flexibly conduct share repurchases, using a total payout ratio of 100% as a guideline. With respect to its dividend policy, in order to enhance the stability and predictability of dividends, the Group has adopted dividend on equity (DOE) as a key dividend indicator, and intends to increase DOE on a phased basis during the period of this Medium-Term Management Plan, setting a target level of approximately 3% in the final fiscal year ending March 31, 2029.

The annual dividend forecast for the fiscal year ending March 31, 2027 is ¥120 per share before taking into account the stock split described below.

In addition, the Company has implemented a stock split to lower the minimum investment amount, making its shares more accessible to investors, and thereby to further enhance share liquidity and expand its investor base. Under the stock split, each share of common stock held by shareholders recorded in the Company's shareholder register as of the record date of September 30, 2026, was split into two (2) shares.

In light of the above stock split, at a meeting of the Board of Directors held on November 12, 2026, the Company resolved and announced, with respect to the shareholder benefit program from the end of March 2027 onward, that the shareholding requirement will continue to cover shareholders holding 100 shares (one unit) or more of common stock, and that the benefit amount (equivalent value) will be expanded to the equivalent of ¥5,000 (previously the equivalent of ¥3,000) during the period of the current Medium-Term Management Plan, which ends in the fiscal year ending March 31, 2029.

Regarding financial results for the six months ended September 30, 2026, net sales increased due to growth in the prescription drug market and contributions from new drugs, including specialty drugs. In terms of profits, the Group continued efforts to ensure appropriate levels of profitability and to review and control selling, general and administrative expenses. However, profits decreased due to rising procurement costs for pharmaceuticals and other items, as well as inflation-driven increases in operating expenses, including higher outsourcing costs.

Based on the above, net sales were ¥1,281,025 million (up 5.1% year on year), operating profit was ¥13,561 million (down 20.0% year on year), ordinary profit was ¥15,343 million (down 14.9% year on year), and profit attributable to owners of parent was ¥12,974 million (down 20.1% year on year).

*2 Medical Care Station (MCS)
: A private timeline-based social networking service (SNS) for medical and nursing care collaboration. It is user-friendly and is compatible with a variety of devices including tablets, smartphones, and computers. With robust security measures, it allows easy access and sharing of necessary information not only within hospitals and facilities but also from outside locations. It facilitates comprehensive community care and interprofessional collaboration by connecting doctors and allied health professionals, nursing care workers, patients, and their families across different professions and roles.

*3 "medimo", a SaaS platform for medical documentation
: A generative AI-powered system that automatically creates highly accurate draft medical records based on conversations during patient consultations. By leveraging speech recognition technology optimized for medical terminology, it contributes to work style reform and improved operational efficiency in healthcare settings.

*4 AI-MS
: A function that replicates, as an AI avatar, the expertise of marketing specialists (MSs) as well as their customer engagement, within a virtual environment on COLLABO Portal offered by Suzuken, and provides information via voice in response to a wide range of questions from healthcare professionals and others. "AI-MS" is a registered trademark of Collabo Square Co., Ltd., a consolidated subsidiary.

*5 COLLABO Portal
: A comprehensive digital health portal operated by Collabo Square Co., Ltd., a wholly owned subsidiary of the Company. It provides one-stop access to a range of functions, including the "Solutions" function, which offers

various services of the Suzuken Group; the "Communications" function, which enables the Group's marketing specialists (MSs), medical representatives (MRs) of pharmaceutical companies, specialized staff, and others to engage remotely with customers via chat and video; and the "Purchasing" function, linked with Amazon Business. By adopting SSO (Single Sign-On: a mechanism that allows users to access multiple systems with a single authentication) and data integration to improve accessibility, it also helps improve operational efficiency in medical and nursing care settings.

Operating results by segment were as follows.

Beginning with the first quarter of the current fiscal year, the Group has revised its reporting segment classification to clarify the business strategies and quantitative targets set forth in the current Medium-Term Management Plan and to present them more appropriately.

The reporting segments have been changed from the previous five segments of Pharmaceutical Distribution, Healthcare Product Development, Community Healthcare and Nursing Care Support, Specialty Drug Contract Distribution, and Healthcare-Related Services to six segments: Pharmaceutical Distribution, Digital, Logistics, Healthcare Product Development, Community Healthcare and Nursing Care Support, and Other Operations. The Specialty Drug Contract Distribution business has been integrated into the Pharmaceutical Distribution segment.

Accordingly, year-on-year comparisons are based on figures reclassified according to the revised segment classification.

For details of the segment revisions, please refer to "Notes on Segment Information etc. 3. Matters concerning changes to reporting segments," described below.

(Millions of yen)

Name of business segment		For the six months ended September 30, 2025	For the six months ended September 30, 2026	Change (%)
Pharmaceutical Distribution	Net sales	1,173,922	1,236,309	5.3
	Operating profit/(loss)	13,682	12,339	(9.8)
Digital	Net sales	1,210	1,690	39.6
	Operating profit/(loss)	(59)	(855)	—
Logistics	Net sales	27,890	28,921	3.7
	Operating profit/(loss)	1,364	1,811	32.7
Healthcare Product Development	Net sales	25,477	25,699	0.9
	Operating profit/(loss)	1,192	284	(76.2)
Community Healthcare and Nursing Care Support	Net sales	46,483	45,719	(1.6)
	Operating profit/(loss)	411	(152)	—
Other Operations	Net sales	2,828	2,816	(0.4)
	Operating profit/(loss)	85	58	(32.0)

(Note) Segment net sales results include intersegment transactions.

(Pharmaceutical Distribution)

The growth of the prescription drug market is presumed to be driven by the expansion of the market for oncological drugs and the contribution from new drugs, including specialty drugs. Under these circumstances, segment net sales totaled ¥1,236,309 million (up 5.3% year on year) due to contributions from new drugs, including specialty drugs, and the growth of the prescription drug market. Operating profit amounted to ¥12,339 million (down 9.8% year on year), due to increases in procurement costs for pharmaceuticals and other items, as well as higher logistics outsourcing costs and other pharmaceutical distribution-related expenses.

(Digital)

Segment net sales increased due to contributions from promotion revenue related to AI-MS at Collabo Square Co., Ltd., among other factors. The segment recorded an operating loss due to factors including an increase in selling, general and administrative expenses associated with upfront investments, such as the development of new services. As a result, segment net sales totaled ¥1,690 million (up 39.6% year on year), and operating loss amounted to ¥855 million, compared with an operating loss of ¥59 million in the same period of the previous fiscal year.

(Logistics)

Segment net sales increased, driven by the revision of contract pricing in the wholesale logistics business and higher distribution volumes in contract logistics services for pharmaceutical manufacturers. Operating profit also increased as a result of continued efforts to improve productivity, despite the escalation of various costs.

As a result, net sales totaled ¥28,921 million (up 3.7% year on year), while operating profit amounted to ¥1,811 million (up 32.7% year on year).

(Healthcare Product Development)

Segment net sales increased despite the impact of drug price revisions, driven by growth in sales of UPASITA IV Injection Syringe for Dialysis for the treatment of secondary hyperparathyroidism and Darbepoetin Alfa BS Syringe for Injection, a long-acting erythropoiesis-stimulating agent, within the pharmaceutical manufacturing business. Operating profit decreased due to a decline in the gross profit margin resulting from increased manufacturing costs and other factors; an increase in research and development expenses associated with progress in the development of paltusotine[*6], an orally administered selective somatostatin receptor type 2 (SSTR2) agonist; and the impact of the suspension of operations at the Kumamoto Plant caused by the 2026 Kumamoto Earthquake, which occurred on July 28, 2026.

As a result, net sales totaled ¥25,699 million (up 0.9% year on year), and operating profit amounted to ¥284 million (down 76.2% year on year).

Due to the impact of the suspension of operations at the Kumamoto Plant, an extraordinary loss of ¥354 million was recorded for the six months ended September 30, 2026. The overall impact is currently under review.

*6 Paltusotine

: A selective somatostatin receptor type 2 (SSTR2) agonist and the world's first once-daily, orally administered small-molecule therapeutic approved in the United States for the treatment of acromegaly in adults for whom surgical intervention is inadequate or not an option. Paltusotine was discovered and designed by Crinetics Pharmaceuticals, Inc. to provide a once-daily oral treatment option for patients with acromegaly as well as for patients with carcinoid syndrome associated with neuroendocrine tumors. It has been designated as an orphan drug by the Ministry of Health, Labour and Welfare for the treatment of acromegaly and pituitary gigantism.

(Community Healthcare and Nursing Care Support)

In the pharmacy business, although the average drug cost and dispensing fee revenue per prescription increased, driven by a higher number of prescriptions for high-priced pharmaceuticals and wider adoption of medical DX-related reimbursement add-ons, net sales declined due to a decrease in the number of prescriptions processed. This reflected both fewer prescription visits associated with longer prescription durations and a reduction in the number of operating pharmacy stores following closures. Operating profit also decreased due to a decrease in gross profit resulting from lower sales revenue, despite efforts to control selling, general and administrative expenses.

In the nursing care business, both net sales and operating profit exceeded plan.

As a result, net sales totaled ¥45,719 million (down 1.6% year on year), while operating loss amounted to ¥152 million, compared with an operating profit of ¥411 million in the same period of the previous fiscal year.

(Other Operations)

Segment net sales decreased due to factors including a decline in the equipment procurement business. Operating profit also decreased due to lower sales revenue. As a result, net sales totaled ¥2,816 million (down 0.4% year on year), and operating profit amounted to ¥58 million (down 32.0% year on year).

(2) Overview of Financial Position for the Semi-Annual Period

Assets, liabilities, and net assets at the end of the current semi-annual consolidated accounting period were as follows:

(Assets)

Total assets as of September 30, 2026 increased by ¥62,171 million from March 31, 2026 to reach ¥1,217,937 million. The main factors of this increase were as follows:

Current assets increased by ¥68,427 million from March 31, 2026. This was mainly due to increases of ¥7,463 million in cash and deposits, ¥32,780 million in notes and accounts receivable - trade, and ¥26,086 million in merchandise and finished goods.

Non-current assets decreased by ¥6,256 million from March 31, 2026. This was mainly due to decreases of ¥2,362 million in property, plant and equipment, ¥1,164 million in intangible assets, and ¥2,729 million in investments and other assets.

(Liabilities)

Total liabilities as of September 30, 2026 increased by ¥59,178 million from March 31, 2026 to reach ¥798,932 million. This was mainly due to increases of ¥55,809 million in notes and accounts payable - trade and ¥9,404 million in “Other” under “Current liabilities,” despite decreases of ¥2,834 million in income taxes payable and ¥2,160 million in provision for bonuses.

(Net assets)

Total net assets as of September 30, 2026 increased by ¥2,992 million from March 31, 2026 to reach ¥419,005 million. The main factors of this increase were as follows:

Shareholders’ equity increased by ¥4,641 million from March 31, 2026. This was mainly due to the posting of ¥12,974 million in profit attributable to owners of parent, despite the payment of ¥3,381 million in dividends of surplus and a decrease of ¥5,131 million due to the purchase of treasury shares.

Accumulated other comprehensive income decreased by ¥1,708 million from March 31, 2026. This was mainly due to a decrease of ¥1,845 million in valuation difference on available-for-sale securities.

(3) Explanation of Forecasts of Consolidated Financial Results and Other Forward-Looking Statements

With regard to the forecasts of consolidated financial results, there have been no changes to the figures announced on May 14, 2026.

2. Consolidated Semi-Annual Financial Statements and Key Notes

(1) Consolidated Semi-Annual Balance Sheets

(Millions of yen)

	As of March 31, 2026	As of September 30, 2026
Assets		
Current assets		
Cash and deposits	116,695	124,159
Notes and accounts receivable - trade	554,190	586,970
Securities	24,976	24,962
Merchandise and finished goods	145,140	171,227
Work in process	1,649	1,536
Raw materials and supplies	5,762	5,774
Other	28,187	30,331
Allowance for doubtful accounts	(429)	(361)
Total current assets	876,172	944,600
Non-current assets		
Property, plant and equipment	139,563	137,201
Intangible assets		
Goodwill	3,523	3,362
Other	12,150	11,147
Total intangible assets	15,673	14,509
Investments and other assets		
Investment securities	79,212	75,646
Other	46,156	46,995
Allowance for doubtful accounts	(1,013)	(1,015)
Total investments and other assets	124,355	121,625
Total non-current assets	279,593	273,337
Total assets	1,155,766	1,217,937

(Millions of yen)

	As of March 31, 2026	As of September 30, 2026
Liabilities		
Current liabilities		
Notes and accounts payable - trade	665,757	721,567
Income taxes payable	10,001	7,166
Provision for bonuses	9,585	7,425
Other	27,707	37,112
Total current liabilities	713,052	773,271
Non-current liabilities		
Retirement benefit liability	2,142	2,177
Other	24,558	23,483
Total non-current liabilities	26,701	25,660
Total liabilities	739,753	798,932
Net assets		
Shareholders' equity		
Share capital	13,546	13,546
Capital surplus	32,147	32,147
Retained earnings	363,582	373,144
Treasury shares	(26,344)	(31,264)
Total shareholders' equity	382,932	387,574
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	32,500	30,655
Revaluation reserve for land	(4,809)	(4,809)
Foreign currency translation adjustment	2,736	3,024
Remeasurements of defined benefit plans	2,516	2,365
Total accumulated other comprehensive income	32,944	31,235
Non-controlling interests	135	195
Total net assets	416,012	419,005
Total liabilities and net assets	1,155,766	1,217,937

(2) Consolidated Semi-Annual Statements of Income and Comprehensive Income

Consolidated Semi-Annual Statement of Income

(Millions of yen)

	For the six months ended September 30, 2025	For the six months ended September 30, 2026
Net sales	1,219,440	1,281,025
Cost of sales	1,125,834	1,188,368
Gross profit	93,606	92,656
Selling, general and administrative expenses	76,647	79,095
Operating profit	16,958	13,561
Non-operating income		
Interest income	83	94
Dividend income	718	680
Share of profit of entities accounted for using equity method	-	546
Rental income from real estate	141	143
Other	433	597
Total non-operating income	1,376	2,062
Non-operating expenses		
Interest expenses	21	21
Share of loss of entities accounted for using equity method	99	-
Rental expenses on real estate	118	120
Other	63	138
Total non-operating expenses	302	280
Ordinary profit	18,032	15,343
Extraordinary income		
Gain on sale of non-current assets	13	18
Gain on sale of investment securities	5,253	4,378
Other	8	51
Total extraordinary income	5,276	4,448
Extraordinary losses		
Loss on sale and retirement of non-current assets	53	103
Loss on disaster	-	354
Loss on valuation of investment securities	16	-
Other	3	0
Total extraordinary losses	73	458
Profit before income taxes	23,234	19,333
Income taxes	6,989	6,339
Profit	16,244	12,994
Profit attributable to non-controlling interests	3	19
Profit attributable to owners of parent	16,241	12,974

Consolidated Semi-Annual Statement of Comprehensive Income

(Millions of yen)

	For the six months ended September 30, 2025	For the six months ended September 30, 2026
Profit	16,244	12,994
Other comprehensive income		
Valuation difference on available-for-sale securities	(1,783)	(1,845)
Foreign currency translation adjustment	(33)	9
Remeasurements of defined benefit plans, net of tax	0	(155)
Share of other comprehensive income of entities accounted for using equity method	(582)	283
Total other comprehensive income	(2,398)	(1,708)
Comprehensive income	13,846	11,285
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	13,842	11,265
Comprehensive income attributable to non-controlling interests	3	19

(3) Consolidated Semi-Annual Statement of Cash Flows

(Millions of yen)

	For the six months ended September 30, 2025	For the six months ended September 30, 2026
Cash flows from operating activities		
Profit before income taxes	23,234	19,333
Depreciation	5,898	6,316
Increase (decrease) in allowance for doubtful accounts	(105)	(65)
Increase (decrease) in other provisions	(1,722)	(2,160)
Increase (decrease) in retirement benefit liability	(349)	(421)
Interest and dividend income	(801)	(775)
Interest expenses	21	21
Loss (gain) on sale and retirement of non-current assets	39	85
Loss (gain) on sale of investment securities	(5,253)	(4,378)
Loss on disaster	-	354
Decrease (increase) in trade receivables	(53,913)	(32,780)
Decrease (increase) in inventories	(517)	(26,005)
Increase (decrease) in trade payables	51,107	55,809
Other, net	16,263	7,306
Subtotal	33,902	22,639
Interest and dividends received	1,284	976
Interest paid	(21)	(21)
Payments associated with disaster loss	-	(252)
Income taxes paid	(8,586)	(8,986)
Payments related to Anti-Monopoly Act	(1,408)	-
Net cash provided by (used in) operating activities	25,171	14,355
Cash flows from investing activities		
Payments into time deposits	(6)	(1,307)
Proceeds from withdrawal of time deposits	6	1,007
Purchase of securities	(6,503)	(7,388)
Proceeds from sale and redemption of securities	17,500	8,400
Purchase of property, plant and equipment	(7,033)	(3,564)
Proceeds from sale of property, plant and equipment	23	73
Purchase of intangible assets	(1,428)	(1,508)
Purchase of investment securities	(31)	(27)
Proceeds from sale and redemption of investment securities	6,180	6,485
Payments for investments in associates	(1,392)	-
Other, net	132	167
Net cash provided by (used in) investing activities	7,447	2,335

(Millions of yen)

	For the six months ended September 30, 2025	For the six months ended September 30, 2026
Cash flows from financing activities		
Proceeds from long-term borrowings	19	55
Repayments of lease liabilities	(128)	(120)
Purchase of treasury shares	(12,184)	(5,131)
Proceeds from share issuance to non-controlling shareholders	-	40
Dividends paid	(3,601)	(3,382)
Net cash provided by (used in) financing activities	(15,895)	(8,539)
Effect of exchange rate change on cash and cash equivalents	(25)	9
Net increase (decrease) in cash and cash equivalents	16,697	8,161
Cash and cash equivalents at beginning of period	118,567	131,604
Cash and cash equivalents at end of period	135,264	139,766

(4) Notes on Consolidated Semi-Annual Financial Statements

<Notes on the Assumption of the Company as a Going Concern>

N/A

<Notes on Significant Changes in the Amount of Shareholders' Equity>

Based on a resolution of the Board of Directors meeting held on August 28, 2026, the Company repurchased 990,000 shares (acquisition price of ¥5,131 million) during the current semi-annual consolidated accounting period ended September 30, 2026.

Primarily for the reason mentioned above, treasury shares amounted to ¥31,264 million as of September 30, 2026.

The Company conducted a stock split of its common stock, with each share split into two (2) shares, effective October 1, 2026. The number of shares stated above is on a pre-stock split basis.

<Notes on Segment Information etc.>

Six months ended September 30, 2025 (From April 1, 2025 to September 30, 2025)

1. Information on sales, income and loss classified by reporting segment

(Millions of yen)

	Reporting segment						Total
	Pharmaceutical Distribution	Digital	Logistics	Healthcare Product Development	Community Healthcare and Nursing Care Support	Other Operations	
Net sales							
Sales to external customers	1,154,430	344	10,518	5,865	46,480	1,802	1,219,440
Intersegment sales and transactions	19,491	866	17,372	19,612	3	1,025	58,371
Total	1,173,922	1,210	27,890	25,477	46,483	2,828	1,277,812
Segment income/(loss)	13,682	(59)	1,364	1,192	411	85	16,677

2. Reconciliation of reporting segment totals to consolidated semi-annual statements of income/(loss) amounts and main components of reconciliation

(Matters concerning reconciliation)

(Millions of yen)

Income	Value
Reporting segment total	16,677
Elimination of intersegment transactions	280
Operating profit on the consolidated financial statements	16,958

3. Information on impairment loss on non-current assets and goodwill by reporting segment

(Significant impairment loss on non-current assets)

N/A

(Significant changes in the amount of goodwill)

N/A

(Significant gain on negative goodwill)

N/A

Six months ended September 30, 2026 (From April 1, 2026 to September 30, 2026)

1. Information on sales, income and loss classified by reporting segment

(Millions of yen)

	Reporting segment						Total
	Pharmaceutical Distribution	Digital	Logistics	Healthcare Product Development	Community Healthcare and Nursing Care Support	Other Operations	
Net sales							
Sales to external customers	1,217,139	576	10,562	5,185	45,712	1,847	1,281,025
Intersegment sales and transactions	19,169	1,113	18,358	20,513	6	969	60,130
Total	1,236,309	1,690	28,921	25,699	45,719	2,816	1,341,155
Segment income/(loss)	12,339	(855)	1,811	284	(152)	58	13,485

2. Reconciliation of reporting segment totals to consolidated semi-annual statements of income/(loss) amounts and main components of reconciliation

(Matters concerning reconciliation)

(Millions of yen)

Income	Value
Reporting segment total	13,485
Elimination of intersegment transactions	75
Operating profit on the consolidated financial statements	13,561

3. Matters concerning changes to reporting segments

Under the new Medium-Term Management Plan, which commenced in the current fiscal year, the Group has positioned its evolution into a next-generation wholesaler as a key initiative. In the pharmaceutical distribution business, in addition to the traditional margin-based business, the Group aims to develop a fee-based business utilizing its functions (i.e., monetizing its capabilities). To support this initiative, the Group has changed its reporting segments as set out below, from the previous business categories to a framework in which each capability is managed and assessed as an independent business.

Segment information for the six months ended September 30, 2025 has been reclassified to conform to the revised reporting segments.

Details of the changes to the reporting segments are as follows:

Previous segments			New segments	
Name	Main companies		Name	Main companies
Pharmaceutical Distribution	SUZUKEN CO., LTD. Sanki Corporation ASTIS Co., Ltd. Shoyaku Co., Ltd. Suzuken Okinawa Yakuhin Co., Ltd. Nakano Yakuhin Co., Ltd. Suzuken Iwate Co., Ltd. S.D.Logi CO., LTD.		Pharmaceutical Distribution	SUZUKEN CO., LTD. Sanki Corporation ASTIS Co., Ltd. Shoyaku Co., Ltd. Suzuken Okinawa Yakuhin Co., Ltd. Nakano Yakuhin Co., Ltd. Suzuken Iwate Co., Ltd. S.D. Collabo Co., Ltd.
Healthcare Product Development	<Pharmaceutical manufacturing> Sanwa Kagaku Kenkyusho Co., Ltd. <Manufacturing of medical equipment and materials> Kenzmedico Co., Ltd.		Digital	Collabo Square Co., Ltd. medimo, Inc.
Community Healthcare and Nursing Care Support	<Pharmacy> UNISMILE Co., Ltd. <Nursing care> Sanki Wellbe Co., Ltd. S-Care Mate Co., Ltd. <Medical and nursing care support> Medicare Collabo CO., LTD.	⇒	Logistics	Collabo CREATE CO., LTD. S.D.Logi CO., LTD. CHUOUNYU CO., LTD.
Specialty Drug Contract Distribution	S.D. Collabo Co., Ltd.		Healthcare Product Development	<Pharmaceutical manufacturing> Sanwa Kagaku Kenkyusho Co., Ltd. <Manufacturing of medical equipment and materials> Kenzmedico Co., Ltd.
Healthcare-Related Services	<External logistics> CHUOUNYU CO., LTD. S.D. Collabo Co., Ltd. (contract logistics services for pharmaceutical manufacturers) <Other> Collabo Square Co., Ltd.		Community Healthcare and Nursing Care Support	<Pharmacy> UNISMILE Co., Ltd. <Nursing care> Sanki Wellbe Co., Ltd. S-Care Mate Co., Ltd. <Medical and nursing care support> Medicare Collabo CO., LTD.
			Other Operations (Note)	Life Support Co., Ltd.

(Note) The Other Operations segment comprises businesses that are not attributable to any of the other reporting segments.

4. Information on impairment loss on non-current assets and goodwill by reporting segment
(Significant impairment loss on non-current assets)
N/A

(Significant changes in the amount of goodwill)
N/A

(Significant gain on negative goodwill)
N/A

<Important Subsequent Events>
(Stock Split)
Based on a resolution of the Board of Directors at its meeting held on May 14, 2026, the Company implemented a stock split with an effective date of October 1, 2026.

1. Purpose of the Stock Split
The purpose of the stock split is to lower the minimum investment amount, making the Company's shares more accessible to investors, and thereby to further enhance share liquidity and expand its investor base.

2. Overview of the Stock Split
(1) Method of the Split
With a record date of September 30, 2026, each share of the Company's common stock held by shareholders recorded in the shareholder register on that date was split into two (2) shares.
Any fractional shares resulting from the stock split were sold in aggregate or purchased by the Company, and the proceeds were distributed to the relevant shareholders in proportion to their respective fractional entitlements.

(2) Number of Shares

(i)	Total number of issued shares before the stock split	:	72,167,204
(ii)	Increase in shares resulting from the stock split	:	72,167,204
(iii)	Total number of issued shares after the stock split	:	144,334,408
(iv)	Total number of authorized shares after the stock split	:	374,000,000

(3) Schedule of the Split

(i)	Public notice of record date	:	September 11, 2026
(ii)	Record date	:	September 30, 2026
(iii)	Effective date	:	October 1, 2026

(4) Other Matters
There were no changes to the Company's total number of authorized shares or its capital stock as a result of the stock split.

3. Impact on Per-Share Information
The impact of the stock split on per-share information is reflected in the summary information.